U.S. District Court Grants Patients Additional Time to Make

               Final Fairness Hearing Rescheduled for May 14, 2002 

  ZURICH, Switzerland, Jan. 4 /PRNewswire/ -- The following was released 
today by Sulzer Medica (NYSE: SM):  
  U.S. District Court Judge Kathleen O'Malley granted patients affected by 
hip or knee implants additional time to decide whether they wish to 
participate in the class action settlement.  The opt-out deadline has been 
extended to May 2, 2002 while the Final Fairness Hearing is now scheduled to 
begin on May 14, 2002. The Final Notice, providing patients with terms of the 
Final Settlement Agreement, will be mailed to class action members on March 1, 
"We welcome the extension of this deadline," said Sulzer Medica CEO Dr. 
Stephan Rietiker, "as it provides us with the opportunity to explain to 
patients the advantages of the settlement in greater detail, which will also 
help to further limit the number of opt-outs.  It is still our goal to provide 
all affected patients with fair and fast compensation by way of this 
Sulzer Medica's subsidiary companies develop, produce, and distribute 
medical implants and biological materials for cardiovascular and orthopedic 
markets worldwide.  The product array includes artificial joint, vertebral, 
and dental implants, trauma products, heart valves, synthetic blood vessels 
and stents for vascular and non-vascular obstructions. (Swiss Stock Market 
symbol: SMEN, New York Stock Exchange symbol: SM).  

     REFORM ACT 1995 

This report contains forward-looking statements including, but not limited 
to, projections of future performance of materials and products, financial 
conditions, results of operations and cash flows, containing risks and 
uncertainties.  These statements are subject to change based on known risks 
detailed from time to time in the Company's Securities and Exchange Commission 
filings and other known and unknown risks and various other factors which 
could cause the actual results or performance to differ materially from the 
statements made herein.  
  This news release is available on the internet at: www.sulzermedica.com. 
The company's quarterly report is available on the Sulzer Medica corporate web 
site at www.sulzermedica.com "Investors" / "Financial reports". 

SOURCE  Sulzer Medica  
-0-                             01/04/2002  
/CONTACT:  Media inquiries, Beatrice Tschanz, Corp. Communications, 
+41-1-308-38-66, or Mobile, +41-79-407-08-78, or fax, +41-1-308-35-06, or 
press-relations@sulzermedica.com, or Andy Bantel, Corporate Communications, 
+41-1-308-37-69, or Mobile, +41-79-231-56-62, or fax, +41-1-308-35-06, or 
Investor Relations, Michael Staheli, +41-1-308-38-64, or fax, 
+41-1-308-35-08, or investor-relations@sulzermedica.com, or Investor Relations 
in the US, Jim Johnson, +1-713-561-63-76, or fax +1-713-561-63-80, or 
investor-relations-us@sulzermedica.com, all of Sulzer Medica/  
/Web site:  http://www.sulzermedica.com /  
CO:  Sulzer Medica 
ST:  Switzerland 
SU:  LAW  
-0- Jan/04/2002 16:49 GMT
Press spacebar to pause and continue. Press esc to stop.